Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : University College London,
Femme et Homme Max 99 ans
University College London,
MAJ Il y a 4 ans
Community navigators study
Background and study aims People with mental health problems are often vulnerable to loneliness, which affects their quality of life and can impede recovery. Loneliness can be defined as a negative ex...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai ouvert aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
University College London,
MAJ Il y a 4 ans
Promoting rapid diagnosis of tuberculosis
Background and study aims Tuberculosis (TB) is a common, infectious condition caused by a bacterial infection. It is generally spread by breathing in tiny droplets released into the air by an infected...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
University College London,
MAJ Il y a 4 ans
Addition of stereotactic body radiotherapy (SBRT) to chemotherapy in locally advanced biliary tract cancers
Feasibility: The main objective of the feasibility part of the trial is to determine if it is feasible to deliver SBRT in a multicentre trial setting in a rare disease. In particular, will clinicians...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
University College London,
MAJ Il y a 4 ans
Investigation into the use of radiofrequency ablation for the treatment of watermelon stomach
Background and study aims Gastric antral vascular ectasia (GAVE), also known as watermelon stomach, is a rare condition in which the lining of the stomach bleeds, giving it the characteristic stripes ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai ouvert aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
University College London,
MAJ Il y a 4 ans
HEpatic Resection Analgesia and Length of time to Discharge
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
University College London,
MAJ Il y a 4 ans
Induction Chemotherapy in Locally Advanced Cervix Cancer
In women with locally advanced cervical cancer, does the addition of weekly chemotherapy prior to chemoradiation alone improve overall survival compared with chemoradiation alone?
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
University College London,
MAJ Il y a 4 ans
A PHASE II EVALUATION OF HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR INTESTINAL T CELL LYMPHOMAS
To assess response rates to primary high dose chemotherapy and autologous transplantation.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
University College London,
MAJ Il y a 4 ans
The development and feasibility of a new service to promote health and well-being in older people who are starting to become frailer: The HomeHealth study
Background and study aims Meeting the needs of the growing number of older people with complex health and social problems remains a challenge to the NHS and social care. As people continue to live lon...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
University College London,
MAJ Il y a 4 ans
Screening and prevention of pre-eclampsia (high blood pressure): Randomised trial of aspirin versus placebo
To examine if the use of low-dose aspirin starting at 11-13 weeks gestation in women at increased risk for pre-eclampsia (high blood pressure) can reduce the incidence and severity of this complicatio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
University College London,
MAJ Il y a 4 ans
A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin’s lymphoma
To evaluate the improvement in overall survival of rituximab combined with CHOP given every 14 days (R-CHOP 14) in comparison to rituximab with CHOP given every 21 days (R-CHOP 21)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant